Moventig

Active Ingredient:: Naloxegol
Origin:: EU

Moventig (Naloxegol)

Q: What is Moventig used for?

Moventig contains naloxegol and is indicated for the treatment of opioid‑induced constipation in patients receiving opioid therapy. It helps restore normal bowel movements by counteracting the constipating effects of opioids on the gastrointestinal tract.

Q: How does naloxegol work?

Naloxegol acts as a selective peripheral µ‑opioid receptor antagonist. By binding to µ‑opioid receptors in the gut, it displaces opioid molecules, reversing the opioid‑mediated inhibition of intestinal motility and allowing normal transit without affecting central pain relief.

Q: What is the usual dose of Moventig?

The dosage of Moventig is determined by the prescribing clinician based on the patient’s condition, opioid regimen, and renal function. The prescriber selects the appropriate strength and frequency according to approved labeling and individual therapeutic needs.

Q: Is Moventig safe during pregnancy or breastfeeding?

Safety data for naloxegol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

Q: How do I order Moventig from GNH India?

To order Moventig, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Moventig compare with other treatments for opioid‑induced constipation?

Moventig (naloxegol) is a peripheral µ‑opioid receptor antagonist taken orally, whereas alternatives such as methylnaltrexone are administered subcutaneously and act similarly on peripheral receptors. Oral administration may be more convenient, but choice depends on patient preference, response, and specific safety considerations.

Q: What are the storage and handling requirements for Moventig?

Moventig should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Q: How is Moventig administered?

Moventig is taken orally, usually with a full glass of water. It can be administered with or without food, but patients should follow the prescribing clinician’s instructions regarding timing relative to meals and other medications.

Q: What are the most serious risks associated with Moventig?

The most serious risks include intestinal obstruction, severe abdominal pain, allergic reactions such as rash or angioedema, and pancreatitis. Patients should seek immediate medical attention if they experience any of these symptoms while using the medication.

Q: Who should not use Moventig?

Moventig is contraindicated in patients with known or suspected gastrointestinal obstruction, severe hepatic impairment, or hypersensitivity to naloxegol or any of the tablet excipients. Clinicians should also exercise caution in patients with significant renal impairment.

Naloxegol, the active ingredient in Moventig, is a µ‑opioid receptor antagonist presented as an oral dosage form for oral administration. It selectively blocks peripheral µ‑opioid receptors, thereby counteracting the gastrointestinal motility inhibition caused by opioid analgesics and is used to treat opioid‑induced constipation in patients on chronic opioid therapy.

GNH India supplies Moventig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products that meet EU regulatory standards and ensuring consistent quality across global markets.

Manufacturer / TM Owner

Grünenthal Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Moventig (naloxegol) is used to manage opioid‑induced constipation, a condition resulting from opioid‑mediated reduction of gastrointestinal motility.
Opioid‑induced constipation: improves bowel movement frequency and reduces stool hardness in patients receiving opioid analgesics.

How It Works

Naloxegol is a peripherally acting µ‑opioid receptor antagonist that does not cross the blood‑brain barrier. By selectively binding to µ‑opioid receptors in the gastrointestinal tract, it displaces opioid agonists, restoring normal enteric neuronal signaling and promoting intestinal transit. The drug is metabolized primarily by CYP3A4 and is excreted unchanged in the feces, providing targeted relief of constipation without affecting central analgesia.

Side Effects

Naloxegol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Abdominal pain
Diarrhea
Nausea
Flatulence

Serious or Rare Side Effects

Intestinal obstruction
Severe abdominal pain
Allergic reactions (e.g., rash, angioedema)
Pancreatitis

Precautions & Warnings

When prescribing Moventig, clinicians should consider several safety precautions to minimize risk.
Assess bowel function before initiating therapy: confirm absence of existing obstruction.
Monitor for abdominal pain or bloating: discontinue if severe symptoms develop.
Avoid use in patients with known or suspected gastrointestinal obstruction.
Use caution in severe hepatic impairment: adjust therapy based on clinical judgment.
Adjust dose in renal impairment: consider reduced exposure in patients with creatinine clearance <30 mL/min.
Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Naloxegol interacts with several drug classes that can alter its exposure or efficacy.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase naloxegol concentrations and risk of toxicity.
Concomitant use with other opioid antagonists (e.g., methylnaltrexone): may reduce therapeutic effect on constipation.
Known or suspected bowel obstruction: co‑administration can exacerbate condition.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure, requiring clinical monitoring.
CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce naloxegol levels, potentially decreasing efficacy.

Frequently Asked Questions

Moventig contains naloxegol and is indicated for the treatment of opioid‑induced constipation in patients receiving opioid therapy. It helps restore normal bowel movements by counteracting the constipating effects of opioids on the gastrointestinal tract.

Naloxegol acts as a selective peripheral µ‑opioid receptor antagonist. By binding to µ‑opioid receptors in the gut, it displaces opioid molecules, reversing the opioid‑mediated inhibition of intestinal motility and allowing normal transit without affecting central pain relief.

The dosage of Moventig is determined by the prescribing clinician based on the patient’s condition, opioid regimen, and renal function. The prescriber selects the appropriate strength and frequency according to approved labeling and individual therapeutic needs.

Safety data for naloxegol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Moventig, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moventig (naloxegol) is a peripheral µ‑opioid receptor antagonist taken orally, whereas alternatives such as methylnaltrexone are administered subcutaneously and act similarly on peripheral receptors. Oral administration may be more convenient, but choice depends on patient preference, response, and specific safety considerations.

Moventig should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Moventig is taken orally, usually with a full glass of water. It can be administered with or without food, but patients should follow the prescribing clinician’s instructions regarding timing relative to meals and other medications.

The most serious risks include intestinal obstruction, severe abdominal pain, allergic reactions such as rash or angioedema, and pancreatitis. Patients should seek immediate medical attention if they experience any of these symptoms while using the medication.

Moventig is contraindicated in patients with known or suspected gastrointestinal obstruction, severe hepatic impairment, or hypersensitivity to naloxegol or any of the tablet excipients. Clinicians should also exercise caution in patients with significant renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.